| Jun-18-19 10:07PM | Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares PR Newswire -23.61% |
| 01:05PM | Migraine-Drug Deal Hype Turns Into a Giant Headache Bloomberg |
| 12:40PM | Here's Why Biohaven Pharmaceutical Plummeted Today Motley Fool |
| 07:31AM | The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga |
| 07:05AM | Should Biohaven Pharmaceutical Holding (NYSE:BHVN) Be Disappointed With Their 36% Profit? Simply Wall St. |
| Jun-17-19 06:00PM | Biohaven Announces Proposed Public Offering Of Common Shares PR Newswire -8.92% |
| Jun-14-19 12:03PM | Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures Investor's Business Daily |
| Jun-11-19 01:50PM | Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Insider Monkey |
| 11:53AM | Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock Zacks |
| May-07-19 11:30PM | Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP-Targeting Monoclonal Antibodies PR Newswire |
| 11:15PM | Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms PR Newswire |
| 06:55AM | Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms PR Newswire |
| May-03-19 07:30AM | Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event PR Newswire |
| May-02-19 01:21PM | These 6 biotech stocks are promising takeover targets MarketWatch |
| 12:41PM | Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Insider Monkey |
| Apr-26-19 06:10AM | Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals |
| Apr-16-19 08:10AM | The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives Benzinga |
| Apr-15-19 08:43AM | Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options Zacks |
| Apr-12-19 06:24PM | Here's Why Biohaven Pharmaceutical Jumped 20% Today Motley Fool +19.96% |
| 06:14PM | CBX: Strong earnings for financials a good start CNBC Videos |
| 04:30PM | General Electric, Biohaven Pharmaceutical Holding, Tesla and More Are Trending Insider Monkey |
| Apr-03-19 07:30AM | Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience PR Newswire |
| Apr-01-19 07:30AM | Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine PR Newswire |
| Mar-18-19 07:30AM | Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application PR Newswire |
| Mar-14-19 07:15PM | Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Sold $5 million of Shares GuruFocus.com |
| 12:52PM | Has Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Got Enough Cash? Simply Wall St. |
| 07:30AM | Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole PR Newswire |
| Mar-13-19 07:30AM | Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant PR Newswire |
| Mar-05-19 07:40AM | Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding New Research Emphasizes Economic Growth GlobeNewswire |
| Feb-28-19 04:30PM | Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results PR Newswire |
| Feb-21-19 10:00AM | What Makes Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a Strong Momentum Stock: Buy Now? Zacks |
| Feb-20-19 07:30AM | Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole PR Newswire |
| Feb-19-19 07:30AM | Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy PR Newswire |
| Feb-04-19 07:30AM | Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist PR Newswire |
| Jan-23-19 07:22AM | The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga |
| 03:00AM | Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy PR Newswire |
| Jan-07-19 03:00AM | Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China PR Newswire |
| Jan-03-19 07:30AM | Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire -5.34% |
| Dec-17-18 07:08PM | Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire |
| Dec-12-18 10:56PM | Biohaven Announces Pricing of Public Offering of Common Shares PR Newswire |
| Dec-10-18 07:19PM | Biohaven Announces Proposed Public Offering of Common Shares PR Newswire |
| 03:00AM | Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study PR Newswire |
| Dec-03-18 03:00AM | Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine PR Newswire +25.39% |
| Nov-29-18 08:09AM | The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved Benzinga |
| Nov-28-18 04:00PM | Biohaven Announces Formation Of BioShin, A Wholly Owned Asia-Pacific Subsidiary PR Newswire |
| Nov-27-18 08:35AM | Factors of Influence in 2018, Key Indicators and Opportunity within Dillard's, Biohaven Pharmaceutical Holding, HTG Molecular Diagnostics, Strongbridge Biopharma, Myriad Genetics, and Beazer Homes New Research Emphasizes Economic Growth GlobeNewswire -7.69% |
| Nov-26-18 03:00AM | Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire |
| Nov-20-18 03:00AM | Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018 PR Newswire |
| Nov-15-18 03:00AM | Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant PR Newswire |
| Nov-14-18 04:06PM | Migraine-Focused Biotech Has A Headache On Quarterly Losses Investor's Business Daily -8.73% |
| 03:00AM | Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results PR Newswire |
| Nov-13-18 08:30AM | Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies PR Newswire |
| Oct-22-18 03:00AM | Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist PR Newswire |
| Oct-10-18 02:42PM | Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Oct-09-18 03:00AM | Biohaven Acquires Option To License Biologic Investigational Agent For Inflammatory And Autoimmune Diseases From The University of Connecticut PR Newswire |
| Sep-12-18 06:19AM | Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine PR Newswire +6.40% |
| 03:00AM | Biohaven Appoints Bob Repella to Board of Directors PR Newswire |
| Sep-06-18 03:00AM | Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine PR Newswire |
| Sep-05-18 08:28AM | The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga |
| 03:00AM | Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy PR Newswire |
| Aug-16-18 09:37AM | The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga +5.95% |
| Aug-14-18 04:15PM | Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results PR Newswire |
| Aug-01-18 07:35AM | Factors of Influence in 2018, Key Indicators and Opportunity within Protagonist Therapeutics, HD Supply, BIOHAVEN PHARM, Big Lots, Clean Energy Fuels, and H&E Equipment Services New Research Emphasizes Economic Growth GlobeNewswire |
| 03:00AM | First Patient Enrolled In Biohaven's Phase 2/3 Mild-To-Moderate Alzheimer's Clinical Trial PR Newswire |
| Jul-31-18 07:15AM | Free Stock Performance Review on Biogen and Three Additional Biotech Stocks ACCESSWIRE |
| Jul-24-18 03:00AM | Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease PR Newswire |
| Jun-28-18 12:30PM | Biohaven Pharma's New Migraine Drug Shows Promise in Late-Stage Test Results TheStreet.com |
| 07:20AM | Free Technical Reports on Cerus and Three Additional Biotech Equities ACCESSWIRE |
| 03:00AM | Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting PR Newswire |
| Jun-21-18 07:15AM | Blog Exposure - Biohaven Signs Royalty Funding and Stock Purchase Agreements with Royalty Pharma ACCESSWIRE |
| Jun-19-18 08:37AM | Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) Is Expected To Breakeven Simply Wall St. |
| Jun-18-18 08:06PM | Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million PR Newswire |
| Jun-13-18 07:30AM | Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region PR Newswire |
| Jun-05-18 03:00AM | Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual Scientific Meeting 2018 PR Newswire |
| May-16-18 08:35AM | What Do Analysts Think About Biohaven Pharmaceutical Holding Company Ltds (NYSE:BHVN) Earnings Trend? Simply Wall St. |
| May-15-18 04:15PM | Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results PR Newswire |
| May-09-18 07:35AM | Our Free Research Report on Biogen and More Biotech Stocks ACCESSWIRE |
| 03:00AM | Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) PR Newswire |
| Apr-22-18 10:00PM | Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine PR Newswire |
| Apr-19-18 07:45AM | Factors of Influence in 2018, Key Indicators and Opportunity within BIOHAVEN PHARM, WEC Energy Group, Axon Enterprise, Tutor Perini, Waste Management, and Twenty-First Century Fox New Research Emphasizes Economic Growth GlobeNewswire |
| 03:00AM | Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles PR Newswire |
| Apr-05-18 09:52AM | Kleo Pharmaceuticals Selected to Present at Biotech Innovation Conference PR Newswire |
| Apr-03-18 03:00AM | Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer PR Newswire |
| Mar-28-18 07:40AM | Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant ACCESSWIRE +8.18% |
| Mar-27-18 04:34PM | Canaccord Sees An 'Intriguing Setup' In Biohaven Following Reaction To Phase 3 News Benzinga |
| 06:47AM | Heres Whats Moving AnaptysBio and Biohaven Pharmaceutical Market Exclusive |
| Mar-26-18 04:13PM | Biohaven Craters By A Third On Migraine Drug Study Rivaling Allergan Investor's Business Daily -7.27% |
| 12:31PM | Here's Why Biohaven Pharmaceutical Holding Co Ltd's Getting Hammered Today Motley Fool |
| 12:19PM | Biohaven's IPO Roadshow Fantasy Meets Grimmer Reality Bloomberg |
| 11:15AM | Biohaven plunges as investors pit migraine data against Allergan's drug Reuters |
| 09:05AM | Biohaven shares drop 23% after migraine drug trial results MarketWatch |
| 03:00AM | Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine PR Newswire |
| Mar-20-18 07:50PM | Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN): Is Breakeven Near? Simply Wall St. |
| Mar-13-18 10:42AM | Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options Zacks |
| Mar-12-18 03:00AM | Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading Institutional Investors PR Newswire |
| Mar-06-18 04:30PM | Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial And Business Results PR Newswire -7.59% |
| 03:00AM | Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine PR Newswire |
| Mar-01-18 03:00AM | Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis® Orally Dissolving Tablet PR Newswire |
| Feb-21-18 03:00AM | Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists PR Newswire |
| Feb-08-18 07:40AM | Analysis: Positioning to Benefit within Great Plains Energy, Flowers Foods, Hasbro, BIOHAVEN PHARM, Vonage, and NOW Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -6.58% |
|
|
|
| Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is headquartered in New Haven, Connecticut. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Doogan Declan | Director | Apr 16 | Sale | 61.92 | 50,000 | 3,096,000 | 926,002 | Apr 16 07:23 PM | | Doogan Declan | Director | Apr 12 | Sale | 53.92 | 38,825 | 2,093,444 | 976,002 | Apr 16 07:23 PM | | Doogan Declan | Director | Mar 26 | Sale | 53.72 | 5,824 | 312,865 | 1,014,827 | Mar 26 06:30 PM | | Bailey Gregory | Director | Mar 25 | Option Exercise | 9.29 | 107,500 | 998,675 | 2,582,601 | Apr 05 05:54 PM | | CHILDS JOHN W | Director | Mar 22 | Option Exercise | 9.29 | 107,500 | 998,675 | 107,500 | Apr 05 05:53 PM | | Doogan Declan | Director | Mar 22 | Sale | 53.66 | 5,351 | 287,135 | 1,020,651 | Mar 26 06:30 PM | | Coric Vlad | Chief Executive Officer | Mar 14 | Sale | 50.02 | 31,893 | 1,595,446 | 440,000 | Mar 14 05:49 PM | | Coric Vlad | Chief Executive Officer | Mar 13 | Sale | 50.02 | 16,145 | 807,573 | 455,783 | Mar 14 05:49 PM | | Tilton John | Chief Commercial Officer | Mar 12 | Option Exercise | 9.29 | 10,000 | 92,900 | 10,000 | Mar 14 05:51 PM | | Coric Vlad | Chief Executive Officer | Mar 12 | Sale | 50.15 | 51,962 | 2,605,894 | 464,045 | Mar 14 05:49 PM | | Tilton John | Chief Commercial Officer | Mar 12 | Sale | 50.11 | 10,000 | 501,100 | 0 | Mar 14 05:51 PM | | Doogan Declan | Director | Mar 01 | Sale | 47.17 | 50,595 | 2,386,519 | 1,026,002 | Mar 01 05:59 PM | | Doogan Declan | Director | Feb 27 | Sale | 45.71 | 23,384 | 1,068,883 | 1,076,597 | Mar 01 05:59 PM | | Doogan Declan | Director | Feb 27 | Sale | 45.02 | 27,045 | 1,217,520 | 373,913 | Mar 01 05:59 PM | | Doogan Declan | Director | Feb 26 | Sale | 44.31 | 20,896 | 925,952 | 400,958 | Feb 26 05:44 PM | | Doogan Declan | Director | Feb 25 | Sale | 45.49 | 13,943 | 634,267 | 1,099,981 | Feb 26 05:44 PM | | Doogan Declan | Director | Feb 25 | Sale | 45.25 | 20,434 | 924,688 | 421,854 | Feb 26 05:44 PM | | Doogan Declan | Director | Feb 22 | Sale | 44.75 | 21,625 | 967,682 | 442,288 | Feb 26 05:44 PM | | GREGORY JULIA P | Director | Feb 21 | Option Exercise | 23.63 | 12,000 | 283,560 | 12,000 | Feb 25 04:40 PM | | GREGORY JULIA P | Director | Feb 21 | Sale | 43.56 | 12,000 | 522,720 | 0 | Feb 25 04:40 PM | | Doogan Declan | Director | Feb 19 | Sale | 45.51 | 1,400 | 63,714 | 1,113,924 | Feb 20 05:40 PM | | Doogan Declan | Director | Feb 15 | Sale | 45.42 | 678 | 30,795 | 1,115,324 | Feb 20 05:40 PM | | AGUIAR ERIC | Director | Feb 04 | Option Exercise | 23.47 | 17,609 | 413,291 | 17,609 | Feb 06 06:21 PM | | Tilton John | Chief Commercial Officer | Jan 10 | Option Exercise | 9.29 | 10,500 | 97,545 | 10,500 | Jan 14 05:50 PM | | Tilton John | Chief Commercial Officer | Jan 10 | Sale | 37.67 | 10,500 | 395,535 | 0 | Jan 14 05:50 PM | | Doogan Declan | Director | Dec 03 | Sale | 41.95 | 40,000 | 1,678,000 | 1,156,002 | Dec 06 04:26 PM |
|
